Riken Corporation

Ryusuke Nakagawa

Kenji Mori

Masaru Taniguchi

Hiroshi Watarai

Takuya Tashiro

Masao Shiozaki

Ken-ichi Fuhshuku

Ken-Ichi Fuhshuku

The invention provides esterified &#x3b1;-galactosylceramides effective for cancer treatment and the like, and a medicament containing same. In particular, the invention relates to a compound represented by the formula (I): wherein Ris a hydrocarbon group having a carbon number of 1 to 30, Ris a hydrocarbon group having a carbon number of 1 to 20, Ris a hydrogen atom or hydrocarbon group having a carbon number of 1 to 5, Rand Rare the same or different and each is a hydrogen atom or a hydrocarbon group having a carbon number of 1 to 5, or Rand Rin combination form a divalent hydrocarbon group having a carbon number of 1 to 5, and optionally form a ring structure together with the adjacent ethylenedioxy, or a salt thereof.

Esterified &#x3b1;-galactosylceramide

The invention provides a glycolipid effective for cancer treatment and the like and a synthetic intermediate therefor, as well as a medicament containing the glycolipid and the like. The glycolipid is represented by the formula (1) or a salt thereof 

Glycolipid and use thereof

The invention provides a pseudoglycolipid effective for cancer treatment and the like and a novel synthesis intermediate therefor, as well as a medicament containing the pseudoglycolipid and the like. The inventive compound is represented by the formula (1), or a salt thereof, wherein each symbol is as defined in the specification.

Pseudoglycolipid and use thereof

Growing community of inventors

Kanagawa, Japan

Ryusuke Nakagawa